July 2013

In the course of 30 years of practicing law I have never seen a corporate defendant backpedal on an agreed-to settlement to the extent BP is attempting to do in the Deepwater Horizon Economic and Property Damages Class Action Settlement. BP still doesn’t understand the law or the facts of this case.

After 23 months, the U.S Food and Drug Administration (FDA) has finally agreed to look at the huge safety discrepancy between generic and brand named drugs. The FDA signaled the move by notifying the Office of Management and Budget of its plans to publish a proposed new rule that would make create similar requirements for generic and brand-name drug makers with respect to how they update their warning labels.